Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma has entered an exclusive license and collaboration agreement with CT Tianqing to develop and commercialize M701, an innovative biological drug for cancer-related complications, which shows promising efficacy and safety in trials. The agreement includes upfront and milestone payments totaling RMB 315 million, with potential sales milestone payments up to RMB 700 million, plus royalties. M701 targets malignant pleural effusion and malignant ascites, conditions affecting over 600,000 patients annually in China, and is expected to set a new standard for treatment.
For further insights into HK:2496 stock, check out TipRanks’ Stock Analysis page.